Desitin
| Desitin Arzneimittel GmbH
|
|
|---|---|
 |
|
| legal form | Company with limited liability |
| founding | 1919 |
| Seat | Hamburg , Germany |
| management | Martin Zentgraf, Christoph Steinschulte, Philipp Bloching |
| Number of employees | 304 |
| sales | 98.4 million euros |
| Branch | Pharma |
| Website | www.desitin.de |
| As of September 30, 2015 | |
The Desitin Arzneimittel GmbH is a medium-sized pharmaceutical companies , family-owned and is based in Hamburg . The main focus of the company's economic activities is in Germany : almost three quarters of sales are achieved in Germany. In addition, Desitin has its own branches in Norway , Sweden , Denmark , Romania and the Czech Republic as well as in Switzerland and Slovakia . There are sales partnerships with other companies for other countries in Europe and Asia (for Austria : Sigmapharm and AOP ).
Desitin focuses on the development, manufacture and distribution of drugs for the treatment of neurological and psychiatric diseases . A particular focus provide means for the treatment of epilepsy is. Desitin is the market leader for antiepileptic drugs in Germany by number of prescriptions. In addition to newer substances and niche products, the range includes all anti -epileptic drugs classified as indispensable by the WHO .
history
The company was founded in Berlin in 1919 as Chemische Fabrik Desitin AG and was based in Tempelhof . It later operated under the name Desitin-Werke Carl Klinke GmbH . The first drug specialty was Desitin ointment , a traditional wound and healing ointment that is still used today. The North American rights to the name Desitin were lost to Desitin Chemical Co. in Providence ( Rhode Island ) during World War II . Desitin Chemical Co. was taken over in 1963 by Pfizer , which in turn sold its Consumer Healthcare division to Johnson & Johnson at the end of 2006 . Johnson & Johnson today distributes a Desitin baby care range in the United States.
After 1945 the company moved to its current location in Hamburg-Fuhlsbüttel . In the years that followed, the company's focus shifted from dermatological drugs to a cardiological focus in the 1960s, to today's focus on drugs for diseases of the central nervous system . Research efforts to own new drugs (u a.. Valproate - and phenytoin - Derivatives ) was not succeed.
Important milestones in the pharmaceutical sector were:
- Phenhydan injection solution as the first ready-to-use phenytoin preparation in 1967
- Orfiril retard first valproate - A sustained-release 1978
- Timonil retard first carbamazepine - A sustained-release 1984
- Orfiril injection solution as the first ready-to-use valproate injection solution in 1996
- Apydan extent than the first oxcarbazepine - A sustained-release 2007
Economic situation
Today's business model includes pharmaceutical improvements of existing drugs, marketing partnerships with research-based pharmaceutical companies and the Launch of pure generics. In 2007 and 2008, Apydan extent ( Oxcarbazepine - Retard ), Clarium ( Piribedil ) and Diacomit ( Stiripentol ) were launched.
Due to its specialization, Desitin has repeatedly managed to partner with larger companies in the past. Desitin took over the niche products Ospolot ( Sultiam ) and Luminal ( phenobarbital ) from Bayer AG in the 1990s . From 1993 to 2000 Desitin was the German sales partner of Glaxo Wellcome for the anti-epileptic Lamictal ( lamotrigine ). Today u. a. a distribution partnership with Novartis for an oxcarbazepine product.
Products
The main products are:
- Almirid ( α-dihydroergocryptine ), a dopamine agonist used to treat Parkinson's disease
- Apydan extent ( oxcarbazepine ), an antiepileptic
- Clarium ( piribedil ), a dopamine agonist used to treat Parkinson's disease
- Desitin ointment , a wound and healing ointment
- Diacomit ( stiripentol ), an anti-epileptic drug
- Diazepam Desitin rectal tubes , an emergency anti-epileptic drug
- Luminal / Luminaletten ( phenobarbital ), an anti-epileptic
- Orfiril ( valproate ), a antiepileptic
- Ospolot ( sulthiame ), an antiepileptic
- Petnidan ( ethosuximide ), an antiepileptic
- Phenhydan ( phenytoin ), an antiepileptic
- Timonil ( carbamazepine , Trimonil in Scandinavia), an antiepileptic
- Timox ( oxcarbazepine ), an antiepileptic agent ( Comarketing with Novartis ' Trileptal)
Science funding
Desitin has provided the prize money for the renowned Alfred Hauptmann Prize for epilepsy research for many years. It is awarded every two years in memory of Alfred Hauptmann , who discovered the clinical effectiveness of phenobarbital as an anti-epileptic in 1912. The award is given to the best scientific work from German-speaking countries in the field of experimental and clinical epileptology. The company also donates the Desitin Young Researcher Prize, which is awarded as a science prize by the Society for Neuropediatrics.
Web links
Individual evidence
- ↑ a b Federal Gazette : Annual financial statements for the financial year from October 1, 2014 to September 30, 2015
- ↑ WHO: Model List of Essential Medicines (17th edition, March 2011 - PDF, English)